Oral cyclophosphamide for active scleroderma lung disease: A decision analysis

Medical Decision Making

Volumn 28, Issue 6, 2008, Pages 926-937

  Khanna, Dinesh ^a,b   Furst, Daniel E ^a   Clements, Philip J ^a   Tashkin, Donald P ^a   Eckman, Mark H ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Cyclophosphamide; Decision analysis; Interstitial lung disease; Pulmonary fibrosis; Scleroderma; Scleroderma lung study

Indexed keywords

CYCLOPHOSPHAMIDE; PLACEBO;

ADULT; ANALYTIC METHOD; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LUNG FUNCTION; MEDICAL DECISION MAKING; NEUTROPENIA; OVERALL SURVIVAL; QUALITY ADJUSTED LIFE YEAR; RISK BENEFIT ANALYSIS; SCLERODERMA; SENSITIVITY ANALYSIS; THEORETICAL MODEL;

CYCLOPHOSPHAMIDE; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; SCLERODERMA, SYSTEMIC;

EID: 57049161521     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X08317015     Document Type: Article

References (35)

1. Steen VD, Conte C., Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994 ; 37 (9). 1283-9.
2. Khanna D., Clements PJ, Furst DE, et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005 ; 52 (2). 592-600.
3. Tashkin DP, Elashoff R., Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006 ; 354 (25). 2655-66.
4. Khanna D., Yan X., Tashkin DP, et al. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum 2007 ; 56 (5). 1676-84.
5. Tashkin DP, Elashoff R., Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007 ; 176 (10). 1026-34.
6. Martinez FJ, McCune WJ Cyclophosphamide for scleroderma lung disease. N Engl J Med 2006 ; 354 (25). 2707-9.
7. Pauker SG, Kassirer JP Decision analysis. N Engl J Med 1987 ; 316 (5). 250-8.
8. Kassirer JP, Moskowitz AJ, Lau J., Pauker SG Decision analysis: a progress report. Ann Intern Med 1987 ; 106 (2). 275-91.
9. Detsky AS, Naglie G., Krahn MD, Naimark D., Redelmeier DA Primer on medical decision analysis: Part 1-getting started. Med Decis Making 1997 ; 17 (2). 123-5.
10. Lau J., Kassirer JP, Pauker SG Decision Maker 3.0. Improved decision analysis by personal computer. Med Decis Making 1983 ; 3 (1). 39-43.
11. Crapo RO, Morris AH, Gardner RM Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981 ; 123 (6). 659-64.
12. Charles C., Clements P., Furst DE Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006 ; 367 (9523). 1683-91.
13. Arias E. National Vital Statistics Report-United States life tables, 2001. DHHS, Centers for Disease Control and Prevention. Vol. 52, No. 14. Available from: URL: http://www.cdcgov/nchs/data/nvsr/nvsr52/nvsr52_14pdf
14. White B., Moore WC, Wigley FM, Xiao HQ, Wise RA Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000 ; 132 (12). 947-54.
15. Talar-Williams C., Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996 ; 124 (5). 477-84.
16. Baker GL, Kahl LE, Zee BC, Stolzer BL, Agarwal AK, Medsger TA Jr. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: long-term case-control follow-up study. Am J Med 1987 ; 83 (1). 1-9.
17. Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a 20-year follow-up study. Arthritis Rheum 1995 ; 38 (8). 1120-7.
18. Baltus JA, Boersma JW, Hartman AP, Vandenbroucke JP The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis 1983 ; 42 (4). 368-73.
19. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992 ; 116 (6). 488-98.
20. Liedberg F., Anderson H., Mansson W. Treatment delay and prognosis in invasive bladder cancer. J Urol 2005 ; 174 (5). 1777-81.
21. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993 ; 329 (14). 987-94.
22. Pearce MS, Parker L., Cotterill SJ, Gordon PM, Craft AW. Skin cancer in children and young adults: 28 years' experience from the Northern Region Young Person's Malignant Disease Registry, UK. Melanoma Res 2003 ; 13 (4). 421-6.
23. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005 ; 43 (7). 736-49.
24. Wirt DP, Giles FJ, Oken MM, Solal-Celigny P., Beck JR Cost-effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma. Leuk Lymphoma 2001 ; 40 (5-6). 565-79.
25. Freedberg KA, Geller AC, Miller DR, Lew RA, Koh HK Screening for malignant melanoma: a cost-effectiveness analysis. J Am Acad Dermatol 1999 ; 41 (5 Pt 1). 738-45.
26. Doubilet P., Begg CB, Weinstein MC, Braun P., McNeil BJ Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985 ; 5 (2). 157-77.
27. Briggs AH, Goeree R., Blackhouse G., O'Brien BJ Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002 ; 22 (4). 290-308.
28. Plastiras SC, Karadimitrakis SP, Ziakas PD, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzelepis GE Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006 ; 55 (4). 598-602.
29. Manger K., Wildt L., Kalden JR, Manger B. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev 2006 ; 5 (4). 269-72.
30. Klippel JH Cyclophosphamide: ovarian and other toxicities. Lupus 1995 ; 4 (1). 1-2.
31. Nadashkevich O., Davis P., Fritzler M., Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006 ; 25 (2). 205-12.
32. Hider SL, Woodhead M., Taylor PM, Bruce IN Lung fibrosis in systemic sclerosis treated with a combination of ciclosporin and azathioprine. Clin Exp Rheumatol 2006 ; 24 (2). 215.
33. Nihtyanova SI, Brough GM, Black CM, Denton CP Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis. Rheumatology (Oxford) 2007 ; 46 (3). 442-5.
34. Plastiras SC, Vlachoyiannopoulos PG, Tzelepis GE Mycophenolate mofetil for interstitial lung disease in scleroderma. Rheumatology (Oxford) 2006 ; 45 (12). 1572.
35. Hoyles RK, Ellis RW, Wellsbury J., et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006 ; 54 (12). 3962-70.